Sea Change In China’s Anti-Cancer Market Shares
This article was originally published in PharmAsia News
Executive Summary
China's hospitals are increasingly turning to alkaloid products such as paclitaxel and docetaxel to treat cancer while immunostimulant anti-cancer products see a decline in use, despite owning the largest market share